Micro-Structural Brain Alterations in Aviremic HIV+ Patients with Minor Neurocognitive Disorders: A Multi-Contrast Study at High Field

GRANZIERA, Cristina, et al.

Abstract
Mild neurocognitive disorders (MND) affect a subset of HIV+ patients under effective combination antiretroviral therapy (cART). In this study, we used an innovative multi-contrast magnetic resonance imaging (MRI) approach at high-field to assess the presence of micro-structural brain alterations in MND+ patients.

Reference

DOI: 10.1371/journal.pone.0072547
PMID: 24039777
Micro-Structural Brain Alterations in Aviremic HIV+ Patients with Minor Neurocognitive Disorders: A Multi-Contrast Study at High Field

Cristina Granziera1,2,3*, Alessandro Daducci3,4,9, Samanta Simioni1, Matthias Cavassini5, Alexis Roche3, Djalel Meskaldji4, Tobias Kober3, Melanie Metral6, Alexandra Calmy7, Gunther Helms8, Bernard Hirschel2, François Lazeyras9, Reto Meuli10, Gunnar Krueger3,11, Renaud A. Du Pasquier1,9

Introduction

It has been suggested that HIV encephalitis is the neuropathological substrate of cognitive disorders [1]. Although HIV does not directly infect neurons or oligodendrocytes, this virus can trigger an inflammatory response with release of cytokines, chemokines, and neurotoxic HIV viral proteins (e.g. gp120).
[1,2], leading to inflammatory infiltrates, as well as myelin and neuronal loss [3,4]. Since the seeding of HIV in the brain occurs early after infection [5], it is possible that HIV-triggered neuro-inflammatory changes occur in the early stages of the disease. Furthermore, combination antiretroviral therapy (cART) may not be sufficient to prevent neuro-inflammatory damages triggered by HIV since some anti-retroviral drugs have a poor rate of penetration-effectiveness into the central nervous system (CNS) [6]. On the other hand, some cART compounds with good penetration might be neurotoxic and provoke cognitive disorders in patients with long-standing treatment [7,8].

In this study, we used a multi-contrast approach at 3 T in a population of HIV patients well treated with cART (undetectable viral load) with and without cognitive impairments (MND+ and MND−) as well as a population of healthy sero-negative controls (HC).

The aim of the study was to determine if MND+ patients showed micro-structural brain alterations, changes in myelination integrity and iron deposition compared to MND− and HC. In this context, we tested the null hypotheses that there are no differences: (i) in micro-structural integrity of global white matter (WM) and cortical gray matter (cGM) among MND+, MND− and HC; (ii) in micro-structural integrity of sub-cortical nuclei involved in cognitive function (basal ganglia and thalamus) and (iii) in micro-structural integrity of WM and cGM in the frontal, parietal, temporal and occipital lobes.

Lastly, we assessed the null hypothesis that no correlation existed between MRI markers of micro-structural alterations in patients and (i) cognitive signs as well as (ii) HIV infection characteristics.

Methods

Subject population

Thirty-six age-matched HIV+ patients with undetectable HIV-1 RNA concentrations (<20 copies/ml for >3 months before study entry) were enrolled: 17 MND+ (53.6 ± 9.1 years, 13 males-M and 4 females-F) and 19 MND− (49 ± 7.2 years, 15 M and 4 F). All participants were enrolled in a randomized pilot study testing the efficacy of rilivastigmine on MND and all the MRI were acquired before the beginning of the therapy. The HIV viral load was measured in the cerebrospinal fluid (CSF) of MND+ patients and was undetectable in all of them. We did not examine the CSF of MND− patients because of ethical reasons (absence of complaints and deficits). All patients were treated with cART.

According to the Frascati criteria [9], HIV+ patients were considered as MND+ when they exhibited deficits in ≥2 cognitive domains (performance ≤ 1 standard deviation below the standardized norms on neuropsychological tests) associated with evidence for mild decreased everyday functioning. Patients with HIV associated-dementia and asymptomatic neurocognitive impairment were not considered for the study. Other exclusion criteria were: (1) history of CNS opportunistic infection, (2) any other opportunistic infection not affecting the brain in the last 12 months before study entry, (3) active drug use, and (4) major depression according to DSM-IV criteria.

Nineteen sero-negative healthy controls (HC: 50 ± 8 years, 9 M and 10 F) were also enrolled in the study. Since none of the HC subjects had cognitive complaints, which has been reported to strongly correlate with normal cognitive functioning in HIV− subjects [10], we only performed a general measure of cognitive function using the mini-mental state examination (MMSE ≥ 25, HC: 28 ± 2) in this category of study subjects, without additional neuropsychological examination. The study was approved by the Ethics Committee of the Lausanne University Hospital (CHUV) and all subjects gave informed written consent for their participation.

Neurobehavioral examination in patients

Neuropsychological testing. All HIV+ participants underwent a comprehensive neuropsychological evaluation, assessing five cognitive domains generally impaired in HIV+ patients with HIV-associated neurocognitive disorder (HAND) [9,11]. The functions examined and the applied referenced tests are reported in detail in Table 1. A deficit score for each domain was then calculated using z-scores retrieved from available normative data correcting for age, gender and educational level.

Psychiatric examination. A psychiatric interview using a French questionnaire (Questionnaire de Santé du Patient) was conducted in order to look for the presence of mood disorders according to the DSM-IV diagnostic criteria. Current mood was assessed using the Hospital Anxiety and Depression scale addressing depressive (HAD-D) and anxious (HAD-A) symptoms, separately. Patients were considered depressed/anxious if the HAD-D/HAD-A subscale score was ≥ 10/21 [11,12].

Table 1. Neuropsychological tests. References are reported in Data S1.
Functional assessment. The impact of cognitive difficulties on everyday functioning was evaluated through the self-assessment of HIV+ patients. In addition, we conducted the Medical Outcome Study HIV Health Survey (MOS HIV), a questionnaire assessing health-related quality of life (QoL).

MRI acquisition

All examinations were carried out on a 3T Magnetom Trio a Tim System (Siemens, Erlangen, Germany) equipped with a 32-channel head coil. A high-resolution T1-weighted Magnetization Prepared Rapid Gradient Echo (MPRAGE) was acquired for anatomical reference (TR/TE = 2300/2.84 ms, inversion time TI = 900 ms, voxel size = 1\x161\x161.2 mm\(^3\), matrix size = 256\x16240\x16160) [13]. A MP2RAGE acquisition with the same voxel and matrix size was used to assess T1 relaxation maps (TR/TE = 5000/2.84 ms, inversion times TI1 = 700 ms and TI2 = 2500 ms, FA1 = 4°, FA2 = 5°) [14] (Figure 1 A). Multiple echo Fast Low Angle SHot Magnetic Resonance Imaging (FLASH) with and without magnetization transfer preparation was acquired (TR/TE = 48/23 ms, voxel size = 2\x162\x162 mm\(^3\), FoV = 240\x16256\x1696, 8 echoes) as described previously [15]. The signals acquired with (MT) and without (M0) the magnetization saturation pulse were used to compute Magnetization Transfer Ratio (MTR) maps, \( \text{MTR} = (\text{M0} - \text{MT})/\text{M0} \times 100 \), Figure 1 B).

The 8 echoes of the M0 volumes were used to compute T2\(^*\) maps by fitting a mono-exponential decay (Figure 1 C).

Susceptibility Weighted Images (SWI) were acquired in a subset of patients and controls (MND+ n = 14, 53.5\pm9.3 years, 12 M and 2 F, MND- n = 16, 48\pm6.4 years, 13 M and 4 F and HC n = 5, 28.6\pm12.5 years, 3 M and 2 F) using a velocity compensated 3D gradient echo sequence (TR = 50/30 ms, FA = 18°, voxel size 0.7\x160.7\x161.4 mm\(^3\), matrix size = 180\x16220\x1652). Phase images were high-pass filtered to correct for low-frequency phase variations [16].

The MRI protocol (including the SWI sequence) was approved by the ethic committee and performed only after obtaining written consent from all participants.

Concepts of quantitative and semi-quantitative MRI contrasts

The MTR is a semi-quantitative marker of structural integrity, which is sensitive to the relative proportion of macromolecules (myelin and cellular proteins) and water [17]. A reduced MTR indicates therefore a loss of macromolecules and/or microscopic oedema [17].

Similarly, the quantitative T1 assessment probes micro-structural properties and longer T1 values indicate a loss in tissue structure (macromolecules) [18,19]. On the other hand, the presence of small molecules with high rotational speed might
Image processing

Information derived from SWI data provides complementary measurements are biased by local iron presence, with higher levels shorten the T1 relaxation times. In addition, quantitative T1

(ii) a threshold obtained by taking the matter nuclei was performed by an experienced neurologist (GC)

visual inspection and eventual manual correction of deep gray

following 6 regions-of-interest (ROI) were extracted in a fully

automated fashion: global

on a Variational Expectation-Maximization algorithm [21]. The

segmentation provided by Freesurfer software www.surfer.nmr.
mgh.harvard.edu in a single healthy subject) to the MPRAGEs

Statistical analysis

Differences in age, gender and educational levels were assessed using a non-parametric ANOVA (Kruskal-Wallis test) among

Multiple regression analysis was performed to assess the influence of MTR, T1, T2* values in all ROIs on global indexes of impairment (cognitive impairment, processing speed, attention, executive, motor and memory index) in MND+ patients. Age and gender were included as covariables. Correction for family-wise error rate was performed for multiple comparisons. SWI data were not used for this analysis, because they were available only in a subset of patients and controls.

Multiple regression analysis was performed to assess the influence of MTR, T1, T2* values in all ROIs on global indexes of impairment (cognitive impairment, processing speed, attention, executive, motor and memory index) in MND+ patients. MND+ and MND− groups did not differ in age, gender, educational level and HIV-characteristics (disease duration since diagnosis, duration of aviremia, nadir of CD4 cell count and cART composition) (Table 2). In particular, there was a similarly high level of CD4+ T cells (>600/μl) and a CPE greater than 7 in both categories, indicating that both MND+ and

Table 2. Demographics, HIV characteristics and neuropsychological results (raw scores and indexes) of MND+ and MND− patients.

<table>
<thead>
<tr>
<th></th>
<th>MND+</th>
<th>MND−</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, y</td>
<td>53.6±9.1</td>
<td>49±7.2</td>
<td>0.1</td>
</tr>
<tr>
<td>Gender, men (%)</td>
<td>13 (76)</td>
<td>16 (84)</td>
<td>0.6</td>
</tr>
<tr>
<td>Education (≥ secondary school), n (%)</td>
<td>12 (71)</td>
<td>18 (95)</td>
<td>0.1</td>
</tr>
<tr>
<td>Duration of HIV infection, y</td>
<td>13.6±7.3</td>
<td>14.7±6.7</td>
<td>0.7</td>
</tr>
<tr>
<td>Duration of HIV aviremia, y</td>
<td>4.9±3.5</td>
<td>6.4±3.7</td>
<td>0.2</td>
</tr>
<tr>
<td>CD4+/μl</td>
<td>648.8±2173</td>
<td>647.1±341.3</td>
<td>0.5</td>
</tr>
<tr>
<td>Nadir CD4+/μl</td>
<td>165.4±88.7</td>
<td>198.4±124.6</td>
<td>0.6</td>
</tr>
<tr>
<td>CPE score for current cART</td>
<td>7.6±1.9</td>
<td>7.3±1.7</td>
<td>0.7</td>
</tr>
<tr>
<td>HDS score</td>
<td>9.4±3.8</td>
<td>14±1.2</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>IHDS score</td>
<td>9±2.1</td>
<td>10.8±1.4</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>ADAS-Cog</td>
<td>7.1±2.9</td>
<td>3.2±1.3</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Global cognitive index</td>
<td>15.6±4.8</td>
<td>3.7±1.7</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Processing speed index</td>
<td>3.3±1.8</td>
<td>1.3±1</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>Attention/working memory index</td>
<td>6.8±2.4</td>
<td>1.4±1.2</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Executive index</td>
<td>3.1±1.2</td>
<td>0.7±0.7</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Memory index</td>
<td>1.6±1.1</td>
<td>0.1±0.3</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Motor index</td>
<td>0.8±1.1</td>
<td>0.2±0.4</td>
<td>0.1</td>
</tr>
</tbody>
</table>

doi:10.1371/journal.pone.0072547.t002

shorten the T1 relaxation times. In addition, quantitative T1 measurements are biased by local iron presence, with higher levels of iron leading to shorter T1 values [18,19]. Similarly, T2* relaxation times strongly depend on the local iron content with high iron leading to shortened T2* values [19]. Lastly, the phase information derived from SWI data provides complementary information to the T2* measurement as it is sensitive to myelin alterations and iron accumulation [20].

Image processing

Bias-field correction and tissue classification were performed on the MPRAGE volumes using an in-house segmentation tool based on a Variational Expectation-Maximization algorithm [21]. The following 6 regions-of-interest (ROI) were extracted in a fully automated fashion: global white and cortical gray matter (WM and cGM), thalamus, caudate, globus pallidus and putamen (Figure 1 D). Subsequently, T1, MTR and T2* maps were aligned to the MPRAGE volume by a rigid-body registration with 6 degrees of freedom and mutual information cost function using ELASTIX [22]. Rigid and non-rigid registration [23,24] were performed to align an in-house template (obtained by manual correction of a segmentation provided by Freesurfer software www.surfer.nmr. mgh.harvard.edu in a single healthy subject) to the MPRAGEs volumes. Average MTR, T1 and T2* values were obtained for all ROIs.

In order to minimize registration and partial volume errors: (i) visual inspection and eventual manual correction of deep gray matter nuclei was performed by an experienced neurologist (GC) (ii) a threshold obtained by taking + and −3 standard deviations from the mean value of T1, T2*, MTR histograms in each single ROI in the healthy control group was applied to T1, T2* and MTR values and (iii) morphological erosion was applied on the binary segmentation masks using a disk with 2 voxels radius as structuring element. A 3 voxel radius resulted to be inappropriate for small ROIs like the basal ganglia. In this ways, we tried to verify the influence of possible contaminations from other tissue types. Statistical significance did not change after applying the threshold and the erosion, therefore the original results are reported.

Volumetric information was computed for all the 6 ROIs mentioned above and for WM and cGM of each lobe (frontal, parietal, temporal and occipital). Each volume was normalized by the total intracranial volume (TIV).

SWI data were analyzed using manual delineation of ROIs in the thalamus, caudate, globus pallidus and putamen (ROI size between 143 and 190 mm3) in order to avoid susceptibility artifacts at the periphery of these structures, which would have hampered the automatic analysis. Phase differences to CSF (assumed to have zero iron content) were used to assess possibly iron related phase accumulations in each nucleus.

Statistical analysis

Differences in age, gender and educational levels were assessed using a non-parametric ANOVA (Kruskal-Wallis test) among MND+, MND− and HC. Differences in HIV-infection characteristics (disease duration since diagnosis, duration of aviremia, nadir of CD4 cell count and cART composition) were assessed using Mann Whitney tests between MND+ and MND− and Bonferroni correction for multiple comparisons.

Non parametric ANOVA was used to assess volumetric differences among all the ROIs.

Statistical analysis of parametric MRI data was performed among the 3 groups (MND+, MND− and HC) using permutation-based univariate t-tests (T1, MTR, T2*), bi-variate tests (T1-MTR, MTR-T2* and T1–T2*) as well as multivariate Hotelling tests (T1, MTR and T2*), with 10,000 permutations and age and gender as covariates. Correction for family-wise error rate was performed for multiple comparisons. SWI data were not used for this analysis, because they were available only in a subset of patients and controls.

Multiple regression analysis was performed to assess the influence of MTR, T1, T2* values in all ROIs on global indexes of impairment (cognitive impairment, processing speed, attention, executive, motor and memory index) in MND+ patients. Age and gender were included as covariables.

Similarly, multiple regression analysis was performed to assess the influence of HIV and therapy-dependent characteristics (disease duration, nadir CD4+, aviremia duration, cART duration) on the MTR, T1 and T2* values in all ROIs.

A linear discriminant analysis (LDA) based on T1, MTR and SWI data was performed using the R-software (www.r-project.org). LDA is a statistical procedure to find a linear combination of features that characterizes or separates two or more classes of objects and events [25]. A leave-one out test was performed for cross-validation of prediction.
MND− were immunocompetent and optimally treated. Furthermore, there was no difference with regard to potentially neurotoxic drugs (see Table S1).

Yet, MND+ patients showed significantly lower scores in all cognitive indexes than MND− patients after Bonferroni correction for multiple comparisons (Table 2).

MRI analysis
Figure 2 and 3 shows the results of the comparison among groups as well as their statistical significance (figures 4 and 5).

Univariate analysis showed (i) lower MTR in WM, cGM, thalamus and caudate as well as (ii) lower T1 in all regions but the thalamus when MND+ patients where compared to HC. The same analysis showed (i) lower MTR in cGM and (ii) lower T1 in WM and cGM of MND− patients vs HC. The univariate comparison between MND+ and MND− patients revealed additionally lower MTR in WM of MND+ subjects and higher T2* in the caudate of MND− patients (figures 2, 3, 4, and 5).

In addition, bivariate and multivariate analysis showed that combination of contrasts revealed significant differences in all regions for MND+ patients vs controls as well as in WM, cGM and caudate of MND− patients vs controls (figures 4 and 5).

No lobar predominance of WM and cGM changes was observed (figures 3 and 5).

In summary, therefore, our data refute the 3 null hypotheses.

No volumetric differences were seen among groups in WM, cGM, sub-cortical nuclei and lobar cGM and WM (see Table S2).

Figure 2. Boxplots representing data from the univariate analysis for WM, cGM, thalamus and basal ganglia. In each box, the central mark represents the median, the edges represent the 25th and 75th percentiles and the whiskers extend to the most extreme data points not considered outliers; outliers are plotted individually as x. HC: green; MND−: red; MND+: blue.

doi:10.1371/journal.pone.0072547.g002

Brain Alterations in Aviremic HIV+ Patients
Multiple regression analyses between MRI markers and neuropsychological indexes in MND+ patients

We found that T1, T2* and MTR values in the sub-cortical nuclei were correlated with the executive index in MND+ patients (p = 0.01 and multiple R² = 0.95, adjusted R² = 0.85). In particular, the parameters that were mostly correlated were the MTR in the putamen (p = 0.05) and the T1 in globus pallidus and putamen (p = 0.03). Age and gender did not appear to play any significant effects on the executive index (p > 0.5).

Multiple regression analyses between MRI markers and biological variables in HIV+ patients

We found that biological variables related to HIV infection were not correlated with MRI markers of disease.

Linear discriminant analysis to differentiate between MND+ and MND- based on MRI data

The linear discriminant analysis based on T1, MTR and SWI data distinguished MND+ from MND-patients with a classification quality of 73% after cross-validation (specificity = 76.5% and sensitivity = 69%). T2* data did not add any significance to the model.

Figure 3. Boxplots representing data from the univariate analysis for lobar WM and cGM. In each box, the central mark represents the median, the edges represent the 25th and 75th percentiles and the whiskers extend to the most extreme data points not considered outliers; outliers are plotted individually as x. HC: green; MND+: red; MND-: blue. FWM: frontal WM; PWM: parietal WM; TWM: temporal WM; OWM: occipital WM; FcGM: frontal cGM; PcGM: parietal cGM; TcGM: temporal cGM; OcGM: occipital cGM.

doi:10.1371/journal.pone.0072547.g003
Discussion

Our study shows the presence of diffuse micro-structural brain tissue alterations in MND+ and MND− HIV+ patients compared to a population of HIV− healthy controls, despite effective treatment and undetectable viremia and virorachia. Most of the observed alterations were more pronounced in MND+ than in MND− patients and were significantly more severe in global WM.

Biological substrate of MTR, T1 and T2* changes

We provide evidence of a significant decrease of MTR in MND+ patients compared to HC in WM, cGM, thalamus and caudate, whereas MND− patients show a less prominent decrease of MTR in cGM (Figures 2 and 4 A–B). Lower MTR indicates a loss of macromolecules (myelin and cellular proteins) and/or a micro-oedema effect [26,27], phenomena that are consistent with an on-going inflammation triggered by HIV [28].

On the other hand, we observe longer T2* relaxation times in the caudate of MND− patients compared to MND+ patients; the same pattern was observed when MND− patients were compared

Figure 4. Graphs showing the respective significance in each ROI for univariate analysis (loop), bivariate analysis (straight line) and multivariate analysis (central circle). Red color indicates p≤0.01 and yellow color indicates p≤0.05. A) hypothesis 1, B) hypothesis 2.

doi:10.1371/journal.pone.0072547.g004
to HC but it did not reach significance (Figures 2 and 4 B). Whether this aspect plays a role in the pathophysiology of MND and/or in the development of HIV infection and response to cART should be determined in prospective studies.

As to the T1 contrast, its behaviour is complex; based on the MTR and T2* behaviour, we would have expected a general increase in T1 in HIV+ patients vs. HC. However, T1 relaxation times in MND− and MND+ patients are generally shorter than
HC (Figures 2, 3, 4, and 5), a behaviour that might reflect lower
iron content (above all in the presence of longer T2*) and/or the
presence of small non-paramagnetic molecules with high rota-
tional speed (tissue debris, cART compounds, etc) [18,29] that
would not influence T2* relaxation times.

Clinical implication of MTR, T1 and T2* changes in
aviremic HIV+ patients

Previous clinical studies reported that cognitive impairment in
HIV-infected individuals can occur in the context of maximal viral
suppression in the serum [30–33]. Some of these studies showed a
correlation between cognitive deficits and age [31,32]. Other
works suggested that cognitive impairment may be an effect of
HIV-induced accelerated aging [34] or neurodegenerative pro-
cesses dependent on chronic inflammation [35]. Recent studies
additionally proposed that insufficient penetration of cART in the
cNS [6] or, on the contrary, a drug-dependent toxic effect [8]
might play a role in MND physiopathology in aviremic HIV+
patients.

Nevertheless, MND+ and MND− patients enrolled in our study
did not differ in terms of age, gender, nor for any HIV-related
characteristics (undetectable plasma HIV viral load in all, current
CD4+ T cell count, CD4+ nadir, duration of aviremia, cART
cPE score[6] as well as composition and duration). Furthermore,
the HIV viral load in the CSF was negative in all MND+ patients,
suggesting that there was no overt HIV replication in the CNS.

In this context, therefore, neither current HIV infection nor
drug response or toxicity appears to be a clear cause of the
presence of MND.

Thus, how to explain that some of these well-treated HIV+
patients develop MND and other not? We show that the micro-
structural differences between HC and MND+ are located in
regions particularly prone to HIV infection (WM and basal
ganglia) [30] as well as in multiple lobes of the cerebral cortex,
which have been previously shown to be thinner in HIV+ patients
with cognitive impairment [31,32]. Thus, despite the fact that
there is no difference in terms of HIV characteristics between
MND+ and MND−, we hypothesize that, upon HIV infection,
some patients are less able than others to control HIV replication
or to limit its collateral damages. This relative inefficiency will lead
to chronic low grade inflammation and tissue damage causing
cognitive disorders.

In favour of this hypothesis, we point to the strong correlation
between MRI results in the sub-cortical gray matter nuclei
(putamen and globus pallidus) and executive impairment. Deficits
in executive function have been largely described in untreated
HIV+ patients [9,36] as a consequence of HIV infection in the
basal ganglia and deep white matter. And previous studies showed
that fronto-striatal circuits connecting the lateral-prefrontal cortex
to the caudate and globus pallidus play a major role in executive
functions (for review see [37]), and the putamen has been recently
reported to be implicated in working memory processes [38].

To date, there are no post-mortem studies reporting chronic
inflammation markers in the brain of HIV+ patients under
effective cART; the few studies available on treated HIV+ patients
did not include aviremic subjects and reported aspecific brain
pathology, which did not relate to premortem neurocognitive
deficits [39,40]. Future works should help elucidate the presence
of subtle chronic inflammatory processes and/or neurodegeneration
in the brain of well-treated HIV+ patients with MND.

Potential of multi-parametric MRI to study subtle brain
abnormalities

Previous MRI studies reported volumetric and morphometric
changes of the whole brain, basal ganglia and white matter in HIV
patients that correlated with cognitive symptoms (for review see
[41]). Notwithstanding, none of these previous works specifically
studied MND+ patients under effective cART and with undetect-
able viral load. Our study does and shows that multi-parametric
MRI at 3T is more sensitive than volumetric analysis to investigate
the presence and the nature of subtle abnormalities.

Last, another important finding of our study is that a linear
discriminant analysis based on T1, MTR and SWI data shows that
multi-parametric MRI provides the capability to distinguish
between MND+ and MND− patients, even when both categories
are optimally treated, reaching classification quality of 75% after
cross-validation. This result is particularly important as it
evidences the potential future role of new clinically-compatible
MRI approach to support diagnostic processes in the absence of
neuropsychological expertise as well as to monitor response to
therapy and disease evolution.

In summary, multi-parametric MRI at high field appears a
powerful means to investigate the physiopathology of minor
neurological signs and a promising sensitive tool to support
medical diagnosis and follow-up. Future validation of these
methods is planned on a prospective study in Lausanne neuro-
HIV cohort.

Supporting Information

Table S1 Presence of potentially neurotoxic drugs (in
%) in MND+ and MND− patients.

Table S2 ROIs volume in mm3.

Data S1 Supplementary data.

Author Contributions

Conceived and designed the experiments: CG GK RADP RM. Performed
the experiments: AD CG SS MC AR DM RADP. Analyzed the data: AD
CG SS MC AR TK DM RADP. Contributed reagents/materials/analysis
tools: GK RADP FL RM. Wrote the paper: CG AD SS MC DM MM AC
GH TK BH FL RM GK RADP.

References

1. Kaul M, Garden GA, Lipton SA (2001) Pathways to neuronal injury and

neuropathogenesis of HIV infection: host-virus interaction and the impact of


Histopathology 45: 549–559.

714.

Validation of the CNS Penetration-Effectiveness rank for quantifying antiretro-

Neurocognitive effects of treatment interruption in stable HIV-positive patients


